Nutra Pharma Corp. (OTCMKTS:NPHC) Ready to Break Out

Nutra Pharma Corp. (OTCMKTS:NPHC) Ready to Break Out

Nutra Pharma Corp. (OTCMKTS:NPHC) Ready to Break Out

NUTRA PHARMA CRP closed up 0.002 at 0.014. Volume was 18% below average (neutral) and Bollinger Bands were 16% wider than normal.

Open High Low Close Volume___
0.011 0.014 0.011 0.014 665,534

Technical Outlook
Short Term: Neutral
Intermediate Term: Bullish
Long Term: Bullish

Moving Averages: 10-period 50-period 200-period
Close:                     0.01                  0.01           0.02
Volatility:             299                 262                 257
Volume:             2,388,655      1,102,753      598,936

Short-term traders should pay closer attention to buy/sell arrows while intermediate/long-term traders should place greater emphasis on the Bullish or Bearish trend reflected in the lower ribbon.


NUTRA PHARMA CRP is currently 12.1% below its 200-period moving average and is in an upward trend. Volatility is high as compared to the average volatility over the last 10 periods. Our volume indicators reflect moderate flows of volume into NPHC.PK (mildly bullish). Our trend forecasting oscillators are currently bullish on NPHC.PK and have had this outlook for the last 10 periods.

Candlesticks Point to a Rally

A big white candle occurred. This is generally considered bullish, as prices closed significantly higher than they opened. If the candle appears when prices are “low,” it may be the first sign of a bottom. If it occurs when prices are rebounding off of a support area (e.g., a moving average, trendline, or retracement level), the long white candle adds credibility to the support. Similarly, if the candle appears during a breakout above a resistance area, the long white candle adds credibility to the breakout.
During the past 10 bars, there have been 4 white candles and 4 black candles. During the past 50 bars, there have been 15 white candles and 31 black candles for a net of 16 black candles.

An engulfing bullish line occurred (where a white candle’s real body completely contains the previous black candle’s real body). The engulfing bullish pattern is bullish during a downtrend. It then signifies that the momentum may be shifting from the bears to the bulls.

If the engulfing bullish pattern occurs during an uptrend (which appears to be the case with NUTRA PHARMA CRP), it may be a last engulfing top which indicates a top. The test to see if this is the case is if the next candle closes below the top of the current (white) candle’s real body.

This is an interesting BioTech, Nutra Pharma Corp. (OTCMKTS:NPHC) the company has drug candidates in HIV and Multiple Sclerosis as well as an existing Pain Management product.

ReceptoPharm (website) is the Nutra Pharma holding that acts as the drug discovery arm for the Company. Nutra Pharma is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases in humans. The emphasis of Nutra Pharma’s approach to drug discovery and the development of new therapeutic agents is based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra.

ReceptoPharm is an innovative biopharmaceutical drug discovery company developing proprietary therapeutic protein products for the billion-dollar biologics market. The Company has two leading products: RPI-MN and RPI-78M.

RPI-MN inhibits the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and Human Immunodeficiency Virus (HIV). It is being developed first for the treatment of HIV.

RPI-78M is being developed for the treatment of Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN). Other neurological disorders that may be served by RPI-78M include Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS).

RPI-78M and RPI-MN contain anticholinergic peptides that recognize the same receptors as nicotine (acetylcholine receptors) but have the opposite effect. In a specific chemical process unique to ReceptoPharm, the drugs are created through a process of chemical modification.

RPI-MN and RPI-78M possess several desirable properties as drugs:

They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose.
They display no serious adverse side effects following years of investigations in humans and animals.
They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs’ stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.
They are easy to administer.
RPI-78M can be administered orally — a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.

The following two tabs change content below.
Shayne Heffernan Funds Manager at HEFFX holds a Ph.D. in Economics and brings with him over 25 years of trading experience in Asia and hands on experience in Venture Capital, he has been involved in several start ups that have seen market capitalization over $500m and 1 that reach a peak market cap of $15b. He has managed and overseen start ups in Mining, Shipping, Technology and Financial Services.